Biocept

Biocept OpEx/Revenue

Delisted

The Operating Expenses to Revenue Ratio of Biocept (BIOC) as of Nov 3, 2026 is 86.14 %. In the previous year, Operating Expenses to Revenue Ratio was 28.69 % — a change of 200.21% (higher).

OpEx/Revenue

86.14 %

YoY

200.21%

Last updated:

Operating Expenses to Revenue Ratio of Biocept is 2022 86.14 % . Operating Expenses to Revenue Ratio of Biocept was 2021 28.69 % . It decreases by 200.21% higher compared to the previous year.

The Biocept OpEx/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OpEx/Revenue
Date
OpEx/Revenue
Jan 1, 2015
1,400.89 USD
Jan 1, 2016
287.73 USD
Jan 1, 2017
208.23 USD
Jan 1, 2018
355.12 USD
Jan 1, 2019
211.03 USD
Jan 1, 2020
55.33 USD
Jan 1, 2021
28.69 USD
Jan 1, 2022
86.14 USD
The Biocept OpEx/Revenue history
YEAROpEx/RevenueYoY
86.14 %+200.21%
28.69 %-48.14%
55.33 %-73.78%
211.03 %-40.57%
355.12 %+70.55%
208.23 %-27.63%
287.73 %-79.46%
1,400.89 %-80.73%
7,270.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

Operating Expenses to Revenue Ratio of Biocept is 86.14 % in 2022.

Operating Expenses to Revenue Ratio of Biocept changed from 28.69 % to 86.14 %, representing a 200.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Expenses to Revenue Ratio Biocept since 2006 – with annual values, charts, and detailed analysis.

The OpEx/Revenue ratio measures total operating expenses as a percentage of revenue. Declining ratios suggest improving operational leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Expenses to Revenue Ratio's Biocept with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Expenses to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Expenses to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Biocept

All Key Metrics — Biocept